anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present invention discloses a pharmaceutical composition for curing qi and blood deficiency and a preparation method thereof. The medical composition is prepared from astragalus root, sucrose, aspartame, citric acid, sodium alginate and potassium sorbate. The preparation processes comprises the steps: the coarse powder of astragalus root is soaked in an alcohol solvent for diacolation, diacolation liquid is collected, the alcohol is recycled via decompression and is concentrated into clear paste for standby. Water is added to the clear paste, the mixture is stirred and filtered to obtain filter liquor for standby. Sucrose, aspartame, citric acid and potassium sorbate are added to water and are dissolved and filtered, filter liquor is mixed with the clear paste filter liquor, the sodium alginate is added, the mixtures are stirred, boiled and kept at 75 to 95 DEG C and are filled into cans, and gel is prepared for oral administration. The medical composition is used for curing qi deficiency, hemophthisis, exterior deficiency, spontaneous sweating, limb weakness, spirit insufficiency or valetudinarianism and spleen and stomach weakness. The pharmaceutical composition has the advantages of good clinical mouth feel and convenient taking and is especially suitable for children.
PROBLEM TO BE SOLVED: To make expensive medicinal base stock economically utilizable and simultaneously improve the quality of the extract by extracting a mushroom (Ganoderma lucidum) efficiently in a high concentration. SOLUTION: This extraction process comprises the first the step where the roughly crushed mushrooms are dipped in warm water at a temp. of 20-45 deg.C, the second step where the mushrooms are extracted with pressurized and hot water at a temp. of 100-130 deg.C, the third step where the extract and the water- containing solid in the second step are separated and the water-containing solid fraction is heat-treated with saturated steam at a temp. of 140-190 deg.C, and the forth step where the heat-treated water-containing solid fraction is extracted again at a temp. of 100-130 deg.C.
We used a randomized controlled trial (RCT) design, randomizing informal heart failure (HF) caregivers meeting our inclusion and exclusion criteria 1:1 to an intervention or control group. After collecting baseline data, we block randomized the caregivers to achieve equal distribution of key variables in each condition. We will block randomize on caregiver sex (male/female), relationship to patient (e.g., spouse), and race. Sex and relationship are factors known to influence perceived caregiving burden and receptivity to intervention. Race was included to assure group balance. The randomization sequence was generated a priori by a statistician independent of the study investigators using a randomly permuted blocks algorithm to ensure equal distribution of these variables in each study arm. The Project Manager notified study staff and participants of their group assignment (intervention or control) by telephone, email or message, as preferred by the individual. Investigators and all staff involved in collecting assessment data were blinded to group assignment until after the data were locked. The health coach providing the intervention and the caregiver participants were not be blinded. All baseline data were collected prior to randomizing. Timing of follow-up assessments were based on day of randomization.

The study intervention was provided to individual caregivers. All caregivers (both groups) were provided with access to an Internet site with excellent health information (HI). The virtual support intervention (ViCCY \["Vicky"\] - Virtual Caregiver Coach for You) was provided through tablet devices provided to caregivers in the intervention group. We provided tablets to all the caregivers, assuring that they had wireless network access so they can access the Internet site providing HI content. Caregivers in the control group received only HI but caregivers in the intervention group received 10 sessions of ViCCY over 6 months.
OBJECTIVES: To determine the spectrum, clinical features and outcomes in systemic lupus erythematosus (SLE) patients with acute abdominal pain (AAP).
METHOD: Medical records of SLE patients in a lupus cohort from January 1987 to June 2023 were reviewed. Patients with AAP requiring hospitalization were identified and categorized into 3 groups: lupus mesenteric vasculitis (LMV), non-LMV, and surgical AAP. Each AAP episode represented one patient.
RESULTS: Of 1,538 patients in the cohort, 62 (4.03%) had 93 episodes of AAP. After exclusion, 31 patients had 39 LMV episodes, and 30 had 40 non-LMV episodes (19 due to surgical AAP). Seventy-six of the 79 AAP episodes (96.20%) were in females, with a mean ± SD age and median (IQR) disease duration of 36.76 ± 13.60 years and 6 (2, 9) years, respectively. Patients in the LMV group had more fever, nausea and vomiting, and diarrhea than those in the non-LMV group. They also had more small bowel involvement, bowel wall thickening, target water enhancement signs, mesenteric vessels engorgement and mesenteric fat cloudiness, and higher SLE disease activity. These differences were more pronounced when compared to the surgical AAP group. Treatment with corticosteroids and immunosuppressive drugs gave favorable outcomes in the LMV group. Two of 40 (5.00%) non-LMV AAP patients died, of which 1 (5.26%) was in the surgical AAP group.
CONCLUSION: LMV was common among SLE patients admitted for AAP. LMV usually presented with fever, gastrointestinal dysmotility symptoms, diffused abdominal pain, together with evidence of active disease. Localized abdominal pain with peritoneal signs favored surgical AAP. Key Points • Lupus mesenteric vasculitis is common among SLE patients presenting with acute abdominal pain. Its presence often associates with gastrointestinal symptoms together with other clinical manifestations of SLE • The signs in abdominal computed tomography findings are not specific and could be observed in other causes of abdominal pain in SLE. Interpretation of these signs should be cautionary and accompanied by history taking and physical abdominal findings • Treatment of lupus mesenteric vasculitis with corticosteroids alone, or in combination with immunosuppressive drugs, usually results in good outcomes.
PCT No. PCT/US93/05702 Sec. 371 Date Apr. 13, 1995 Sec. 102(e) Date Apr. 13, 1995 PCT Filed Jun. 14, 1993 PCT Pub. No. WO93/25688 PCT Pub. Date Dec. 23, 1993Methods for the recombinant production of saporin-containing proteins, including cell surface binding protein-saporin fusion proteins, are provided. The resulting fusion proteins are cytotoxic to targeted cells. In preferred embodiments, methods are provided for the production of basic fibroblast factor (bFGF)-saporin fusion proteins by culturing Escherichia coli that has been transformed with a vector containing DNA encoding bFGF linked via a spacer peptide to the amino terminus of a cytotoxic portion of a saporin polypeptide to obtain expression of the DNA, and isolating the resulting FGF-saporin fusion protein. FGF-saporin fusion proteins and saporin proteins containing from about 5 to 12 amino acid N-terminal extensions are also provided.
Methods and apparatus are provided for an exfoliating anti-acne face cleansing composition. The exfoliating anti-acne face cleansing composition includes an anti-acne active ingredient and exfoliating particles. The exfoliating anti-acne face cleansing composition further includes a high molecular weight polymer having a molecular weight at least equal to ten kiloDaltons (kD) and a moisturizer. A ratio of the high molecular weight polymer to total formula solids is between 8:100 and 12:100. A ratio of the high molecular weight polymer to an amount of moisturizer is between 4:10 and 9:10. A pH of the exfoliating anti-acne face cleansing composition is less than 5.0.
Like other topical corticosteroids, triamcinolone acetonide has anti-inflammatory, antipruritic, and vasoconstrictive properties. The mechanism of the anti-inflammatory activity of the topical steroids, in general, is unclear. However, corticosteroids are thought to act by the induction of phospholipase A2 inhibitory proteins, collectively called lipocortins. It is postulated that these proteins control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor, arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholipase A2. 

Pharmacokinetics   
The extent of absorption through the oral mucosa is determined by multiple factors including the vehicle, the integrity of the mucosal barrier, the duration of therapy, and the presence of inflammation and/or other disease processes. Once absorbed through the mucous membranes, the disposition of corticosteroids is similar to that of systemically administered corticosteroids. Corticosteroids are bound to the plasma proteins in varying degrees. Corticosteroids are metabolized primarily in the liver and are then excreted by the kidneys; some corticosteroids and their metabolites are also excreted into the bile.
In vivo astrocyte-to-neuron (AtN) conversion induced by overexpression of neural transcriptional factors has great potential for neural regeneration and repair. Here, we demonstrate that a single neural transcriptional factor, Dlx2, converts mouse striatal astrocytes into neurons in a dose-dependent manner. Lineage-tracing studies in Aldh1l1-CreERT2 mice confirm that Dlx2 can convert striatal astrocytes into DARPP32+ and Ctip2+ medium spiny neurons (MSNs). Time-course studies reveal a gradual conversion from astrocytes to neurons in 1 month, with a distinct intermediate state in between astrocytes and neurons. Interestingly, when Dlx2-infected astrocytes start to lose astrocytic markers, the other local astrocytes proliferate to maintain astrocytic levels in the converted areas. Unexpectedly, although Dlx2 efficiently reprograms astrocytes into neurons in the gray matter striatum, it also induces partial reprogramming of astrocytes in the white matter corpus callosum. Such partial reprogramming of white matter astrocytes is associated with neuroinflammation, which can be suppressed by the addition of NeuroD1. Our results highlight the importance of investigating AtN conversion in both the gray matter and white matter to thoroughly evaluate therapeutic potentials. This study also unveils the critical role of anti-inflammation by NeuroD1 during AtN conversion.
PURPOSE: A method for sterilizing cosmetic compositions is provided to effectively annihilate fungi generated from the raw material of cosmetic composition. CONSTITUTION: A method for sterilizing cosmetic compositions is as follows. Cosmetic compositions containing one or more materials and aquatic medium are prepared. The cosmetic compositions are sterilized at 60-80deg.C. The cosmetic compositions are sterilized with voltage of 1.5-100V. The sterilization of the cosmetic compositions are executed for 1-3 hours.
<P>PROBLEM TO BE SOLVED: To provide a medicine effective for a disease (e.g. multiple sclerosis) caused by the excessive reaction of Th2 or Th17 of a helper T cell, and to provide an effective screening method of the medicine.  <P>SOLUTION: The medicine for treating or preventing the disease caused by the excessive reaction of the Th2 or the Th17 contains a dopamine D2-like receptor agonist as an active ingredient. The screening method of the medicine uses the bond to the dopamine D2-like receptor and/or the active effect on the dopamine D2-like receptor as an indicator. Especially, at least one of pramipexole hydrochloride hydrate and ropinirole hydrochloride is preferable as the medicine.  <P>COPYRIGHT: (C)2010,JPO&INPIT
INTRODUCTION: Pathogen genomics, where whole genome sequencing technologies are used to produce complete genomic sequences of pathogens, is being increasingly used for infectious disease surveillance and outbreak response. Although proof-of-concept studies have highlighted the viability of using pathogen genomics in public health, few studies have investigated how end-users utilize pathogen genomics in public health. We describe a protocol for a study that aims to identify key factors that influence the use of pathogen genomics to inform public health responses against infectious diseases in Australia and New Zealand.
METHODS: We will use qualitative comparative analysis (QCA), a case-oriented methodology that systematically compares and analyses multiple cases (or 'units of analysis'), to identify multiple pathways leading to the use of pathogen genomics results in public health actions. As part of the process, we will develop a rubric to identify and define the use of pathogen genomics and individual factors affecting this process. Simultaneously, we will identify cases where pathogen genomics has been used in public health across Australia and New Zealand. Data for these cases will be collected from document review of publicly available and confidential documents and semi-structured interviews with technicians and end-users and summarized in a case report. These case reports will form the basis for scoring each case on the extent of the use of pathogen genomics data and the presence or absence of specific factors such as the ease of extracting essential information from pathogen genomics reports and perceptions toward pathogen genomics. Using the scores, cases will be analyzed using QCA techniques to identify pathways leading to the use of pathogen genomics data. These pathways will be interpreted alongside the cases to provide rich explanations of the use of pathogen genomics in public health.
DISCUSSION: This study will improve our understanding of the key factors that facilitate or hinder the use of pathogen genomics to inform public health authorities and end-users. These findings may inform ways to enhance the use of pathogen genomics data in public health.
Individuals who develop chronic harmful inflammation in association with self-reactive autoantibodies or T cells are said to have autoimmune diseases. The causes of these diseases are unknown but they are thought to occur in genetically susceptible individuals after exposure to selected environmental agents. There are many forms of these diseases, but we have been focusing on one of the rarest and most poorly-studied group of autoimmune disorders, known as the Idiopathic Inflammatory Myopathies (IIM). This heterogeneous group of diseases includes polymyositis, dermatomyositis and related disorders. This is a natural history protocol designed to continue our study of these diseases and begin the evaluation of related connective tissue disorders associated with environmental exposures. We plan to further delineate important groups of patients and familial cases, and obtain useful material for further investigations of the clinical presentations, etiology, pathogenesis, and immunologic abnormalities of autoimmune/connective tissue diseases. Clinical data and patient blood, urine and tissue specimens have been collected by referring physicians and sent to us. The blood samples have been separated into cells and plasma, frozen and then placed into cell and plasma banks. Often the diagnosis of an IIM can be confused with other illness (such as adult-onset dystrophies), and therefore, we have also included patients with other illnesses (who are referred with a preliminary diagnosis of an IIM or an unknown myopathy), including patients with other autoimmune diseases. In order to understand more fully the genetic risk factors for these diseases, family members of selected patients who have several blood relatives with autoimmune or connective tissue diseases will also be studied. In summary, this natural history protocol will attempt, through a series of hypothesis-testing and hypothesis-generating studies, to obtain new information regarding the clinical presentation, risk and protective factors, pathogeneses and prognostic features for myositis and related conditions.
PROBLEM TO BE SOLVED: To produce the subject unique molded product, capable of manifesting excellent chewing brittleness and melting in a mouth and having a low sweetness by crystallizing and including a trehalose dihydrate crystal therein. SOLUTION: This molded product contains (A) an edible raw material other than a trehalose (e.g. a thickener, a nutrient, a favorite food or a physiologically active substance) and is obtained by crystallizing and including (B) a dihyclrate crystal of the trehalose (preferably α, α-trehalose). The crystallinity of molded product measured by a powder X-ray diffractometry is preferably >=40% when paying attention to the ingredient B contained therein.  The resultant molded product can be produced by preparing a supersaturated aqueous solution of the trehalose, containing, e.g. the trehalose and the ingredient A and having about 5-30% moisture content, then starting the crystallization of the ingredient B from the supersaturated aqueous solution, subsequently molding the resultant supersaturated aqueous solution according to a conventional method, further carrying out the crystallization and solidification of the ingredient B and, as necessary, drying the resultant molded product. The obtained product has <3.0 kg penetration breaking strength measured by a rheometer.
Participants played a set of three modified stop-signal reaction time tasks designed by NeuroScouting, LLC at home for approximately 5 days a week (25 min/day) for 4-weeks. This condition had no change in difficulty (non-adaptive gameplay).
Participants randomized to the wait-list attention control group will continue to undergo standard care for 12 weeks. They will continue to wear the Garmin activity tracker and can view their activity but will not be given an exercise program. They will be contacted by a study coordinator via telephone every 2 weeks for health education. During this time, they will review resources and healthy lifestyle guidelines for people with epilepsy, including healthy diet, medication compliance, seizure precautions, stress management, and sleep hygiene.
The present invention comprises a method for controlling (e.g. inhibiting) or killing microorganisms in an aqueous environment. The method includes the addition of an effective amount of monochlorourea or modified monochlorourea to an aqueous solution. This aqueous solution may be a cooling water system, a recreational water system, a water treatment facility, or any circulating water system (i.e. a papermaking facility). A method of producing monochlorourea or modified monochlorourea is also disclosed.
Pancreatic lipase (PNLIP) is the major lipolytic enzyme secreted by the pancreas. A recent study identified human PNLIP variants P245A, I265R, F300L, S304F, and F314L in European cohorts with chronic pancreatitis. Functional analyses indicated that the variants were normally secreted but exhibited reduced stability when exposed to pancreatic proteases. Proteolysis of the PNLIP variants yielded an intact C-terminal domain, while the N-terminal domain was degraded. The protease-sensitive PNLIP phenotype was strongly correlated with chronic pancreatitis, suggesting a novel pathological pathway underlying the disease. To facilitate preclinical mouse modeling, here we investigated how the human mutations affected the secretion and proteolytic stability of mouse PNLIP. We found that variants I265R, F300L, S304F, and F314L were secreted at high levels, while P245A had a secretion defect and accumulated inside the cells. Proteolysis experiments indicated that wild-type mouse PNLIP was resistant to cleavage, while variant I265R was readily degraded by mouse trypsin and chymotrypsin C. Variants F300L, S304F, and F314L were unaffected by trypsin but were slowly proteolyzed by chymotrypsin C. The proteases degraded the N-terminal domain of variant I265R, leaving the C-terminal domain intact. Structural analyses suggested that changes in stabilizing interactions around the I265R mutation site contribute to the increased proteolytic susceptibility of this variant. The results demonstrate that variant I265R is the best candidate for modeling the protease-sensitive PNLIP phenotype in mice.
This article examines the impact of the reporting practice and paper technologies like forms on reports that were later used for national morbidity statistics by studying the Swiss reporting system for infectious diseases between 1886 and 1921. Analysing the production processes of notifications shows the difficulties and solutions in the implementation of the statutory reporting process. Two disease outbreaks-a smallpox outbreak in Schaffhausen and a typhoid outbreak in the canton of Lucerne-serve as case studies. It is shown that reports are not only objective representations of diseases, but also symbolize the medico-social interactions that produce them, timed by administrative tools like reporting forms and the act of reporting. This destabilises historical statistics and illustrates the complexity of the historical source material, as these interactions and their impact on reporting must be considered. These findings are further supported by examining the Swiss reporting system during the Spanish flu of 1918 and its failure to record influenza cases.
PURPOSE: A composition containing extract isolated from lactic acid bacteria culture liquid is provided to suppress IL-6 secretion and to treat inflammatory diseases and cancer. CONSTITUTION: A composition for treating inflammatory diseases contains extract of lactic acid bacteria culture liquid. The lactic acid bacteria are Lactobacillus, Lactococcus, Leukonostoc, Pediococcus, or Bifidobacteria. The extract contains supernatant of the culture liquid except for the bacteria. The supernatant contains heat resistant ingredients. A composition for treating cancer contains the extract. A composition for treating thrombokinesis-related diseases contains the extract. A method for treating inflammatory diseases or cancer comprises a step of administering the extract.
The HAwI and HBwI patients enrolled into the concizumab phase 2 trial (NN7415-4310) at time of transfer will be offered enrolment into this trial. It is required that these patients are on concizumab prophylaxis up until enrolment into the trial. These patients will continue concizumab prophylaxis.
The invention relates to a drug for treating cervicitis, cervical erosion, hypertrophy of uterus, nodular change and other organic lesions of genital organs with irregular uterine bleeding. Most of the clinical treatments of cervicitis, cervical erosion and other diseases adopt external treatment methods, which can only treat the symptoms, but can not treat the root causes of diseases. The medicine realizes that evil-poison and blood stasis are root causes for the evolution of the diseases from the treatments of numerous cases and proposes that the organic lesions of the gynecological genital organs can be fundamentally cured by combining the removal of the blood stasis on the basis of detoxification (anti-bacterial and anti-inflammation). The drug of the invention is composed of thirteen medicines of glabrous greenbrier rhizome, bittersweet herb, black nightshade herb, Chinese brake herb, heartleaf houttuynia herb, agrimony, barbed skullcap herb, Japanese thistle herb, red paeony root, nutgrass galingale rhizome, membranous milkvetch root, liquoric root, himalayan teasel root and so on according to a certain proportion. With the functions of removing toxicity, eliminating blood stasis, clearing uterus and strengthening vital qi, the drug has immediate efficacy for cervicitis, cervical erosion, hypertrophy of uterus, nodular change and other organic lesions of genital organs with the irregular uterine bleeding, and the long-term clinical practices prove that the drug has special efficacy. The drug can be prepared into a decoction, which can also be prepared into pills, oral liquor, granules, tablets, capsules and other products.